ClinicalTrials.gg
CompletedNCT02055638AVN009Updated Jul 21, 2023Results posted

Safety, Tolerability and Activity of SRX246 in Adults With Intermittent Explosive Disorder

A Phase 1/2 interventional study of SRX246 and Placebo in Intermittent Explosive Disorder, sponsored by Azevan Pharmaceuticals. Completed at 7 sites in United States. Open to participants aged 21 Years to 55 Years. Per ClinicalTrials.gov, last updated 2023-07-21.

Sponsored by Azevan Pharmaceuticals · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
97
Allocation
Randomized
Ages
21 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies in Disruptive, Impulse Control, and Conduct Disorders with a site in United States — 8 open to participants now, 8 under way, none of them phase 3. Disruptive, Impulse Control, and Conduct Disorders · United States.

Enrollment
5th of 28
97 · median 48
Started
2014
the only one that year
Phase 1/2
Only one
of the 31
Registered
18th of 31
by date
Lead sponsor
1 of 31
Azevan Pharmaceuticals

Among the 31 studies in Disruptive, Impulse Control, and Conduct Disorders with a site in United States, this one is the 5th largest by enrollment of the 28 interventional ones that give a count, is the only one that started in 2014, is the only one in phase 1/2, and was the 18th registered.

Disruptive, Impulse Control, and Conduct Disorders

56 studies on the registry are indexed under Disruptive, Impulse Control, and Conduct Disorders; 17 are open to participants now.

Browse Disruptive, Impulse Control, and Conduct Disorders studies →

Open to participants now

8 of the 31 studies in Disruptive, Impulse Control, and Conduct Disorders with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 15 Disruptive, Impulse Control, and Conduct Disorders studies recruiting now, 4 (27%) set no upper age limit and 10 (67%) stop at 75 or younger; none take children under 18; 5 take healthy volunteers.

This study: 21 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Disruptive, Impulse Control, and Conduct Disorders with a site in United States, or all of them as a file.
02

Study summary

This study is designed to explore the safety and tolerability, and to compare the activity of SRX246 against placebo, in adults with Intermittent Explosive Disorder (IED).

Adult Male and Female subjects with a current diagnosis of IED will be enrolled. After a two-week baseline lead-in phase, study subjects who continue to meet enrollment criteria will be randomized to either SRX246 or Placebo treatment groups.

Study subjects will be examined and asked to answer questionnaires at weekly scheduled visits throughout the trial. The study results will be determined based on any changes observed over the study period.

Read the detailed description

This exploratory Phase II study has been designed to examine the safety and tolerability profile, and to compare the activity of the novel V1a vasopressin antagonist (SRX246) against placebo, in adults with DSM-5 Intermittent Explosive Disorder (IED).

Adult Male and Female subjects with a current DSM-5 diagnosis of IED will be enrolled. All subjects will undergo systematic diagnostic assessment for DSM-5 Axis I and II disorders. Subjects with DSM-5 IED (without current, co-morbid, DSM-5 Major Depression) whose: (a) Life History of Aggression (LHA) score is > 12, (b) Overt Aggression Scale Modified (OAS-M) "Irritability" score is > 6 and, (c) screening OAS-M "Aggression" score is > 15, will be entered into a two-week baseline lead-in phase.

After the lead-in phase, study subjects who continue to meet OAS-M criteria will be randomized to one of the two (2) treatment conditions and stratified by gender so that equal numbers of males and females are assigned to SRX246 and Placebo Groups. Those who do not meet the criteria will exit the protocol at that time. Treatment Conditions: (a) 8-week course of SRX246 (4 weeks at 120 mg bid, and 4 weeks at 160 mg bid) or (b) 8-week course of Placebo, followed by a one-week "taper" to withdraw subjects from study medication.

IED subjects in all conditions will have structured diagnostic interview sessions and questionnaires administered throughout the trial. Blinding to treatment condition will be maintained by using different personnel for these activities. Analysis of a change from baseline in the diagnostic measures will be performed.

03

Conditions studied

  • Intermittent Explosive Disorder

Keywords

  • Intermittent Explosive Disorder
  • IED
  • Aggression
  • SRX246
  • Vasopressin 1a Receptor Antagonist
  • V1a
04

Who can participate

Ages eligible
21 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or Female (Women of child bearing potential must be non-pregnant, non-lactating and agree to be on an acceptable method of .)
  • Age 21 to 55 years, inclusive.
  • In good general physical health as determined by medical history, a baseline physical examination, vital signs, clinical laboratory tests and (EKG) measurement.
  • Current IED by
  • LHA-Aggression ≥ 12.
  • OAS-M Irritability score ≥ 6, and OAS-M Total Aggression score ≥ 15, respectively at Visit 1
  • Mean Irritability and Total Aggression scores for Visit 2 and Visit 3, ≥ 6 and ≥ 15, respectively.
  • Subject is willing and able to sign written prior to receipt of any study medication or beginning study procedures.
  • Subject is willing and able to follow instructions, comply with the protocol requirements and make all required study visits.

Exclusion criteria

Exclusion Criteria:

  • Subject with a positive test for alcohol and/or drugs of abuse at screening or at any time during the study.
  • Presence of any of the following serious and active medical conditions: Seizure Disorder (n.b.: history of \< 2 febrile seizures prior to one year of age is acceptable); Demyelinating or Progressive Degenerative Disorders; central nervous system (CNS) Infection; Progressive Degenerative Neurological Disorder; Ischemic Heart Disease, Respiratory Disease, Renal Disease; Liver Disease; Type I Diabetes; Malignant Neoplasm; Hyper- or Hypo-Coagulopathy; Acquired Immuno-Deficiency Syndrome (AIDS).
  • Routine or as needed consumption of medications or herbal supplements that the subject is unable or unwilling to discontinue during the study.
  • Other ongoing psychotherapeutic treatment for the treatment of IED or anger begun less than three months before entry into this study.
  • Not Current IED.
  • LHA score \< 12 at Visit 1 (screen).
  • OAS-M Irritability score \< 6 or OAS-M Total Aggression score \< 15 at Visit 1 (screen).
  • Current major depressive episode or life history of bipolar disorder, schizophrenia, organic mental syndrome, or mental retardation.
  • Current DSM-5 Substance Use Disorder of moderate or greater severity (i.e., ≥ 4 Substance Use Disorder (SUD) symptoms).
  • Active suicidal ideation as determined by clinical assessment and Columbia-Suicide Severity Rating Scale (C-SSRS).
  • Evidence of any out-of range laboratory value at screening that has not been reviewed, approved and documented as not by the Study Investigator.
  • A history of significant drug allergy or systemic allergic disease (e.g., urticaria, atopic dermatitis), or any known/suspected to SRX246.
  • A general medical or psychological condition or behavior, including current substance dependence or abuse that, in the opinion of the investigator, might not permit the subject to complete the study or sign the .
  • Unwilling/unable to sign informed consent document.
  • Any clinically significant abnormality on screening resting 12-lead (e.g., heart block, conduction disorders, ventricular and/or atrial arrhythmias).
  • Any other condition or clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening that, in the opinion of the Study Investigator, would make the subject unsuitable for the study or put them at additional risk.
  • Inability to understand or follow study instructions.
  • Treatment with an drug within 30 days preceding the first dose of study medication.
  • Women who are currently breastfeeding and/or lactating.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
97 participants (actual)

Study arms

  • Experimental
    SRX246

    SRX246 capsules, 120mg bid for 4 weeks followed by 160mg bid for 4 weeks

    Drug: SRX246

  • Placebo comparator
    Placebo

    Placebo capsules to match the amount of SRX246 capsules for 8 weeks

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability

    measured as the number of participants with adverse events

    Time frame: from initial dose of intervention until completion of the study up to 8 weeks

Other outcomes

  1. Overt Aggression Scale Modified (OAS-M) Total Aggression Score

    Change from Baseline OAS-M Score. Higher values represent a worse outcome. The OAS-M contains 3 scales: Aggression (Questions \[Q\]1 to 4), Irritability (Q5 to 6), and Suicidality (Q7 to 7b). Aggression total score was calculated by summing the weighted scores in Q1 to 4. Scores for each question ranged from 0 (no events) to 5 (very severe events). Total scores ranged from 0 (no aggression) to any number with no upper limit depending on the frequency of aggressive behavior in a week.

    Time frame: Comparison of baseline score to score at end of treatment period of 8 weeks

07

Results

Posted Oct 29, 2019

Participant flow

Participant flow — Overall Study
MilestoneSRX246Placebo
Started4948
Completed3940
Not completed108

Outcome measures

PrimarySafety and Tolerability

measured as the number of participants with adverse events

Time frame:
from initial dose of intervention until completion of the study up to 8 weeks
Reported as:
Number · participants
Safety and Tolerability
participantsSRX246Placebo
adverse events (AE)2821
serious adverse events (SAE)00
Other pre-specifiedOvert Aggression Scale Modified (OAS-M) Total Aggression Score

Change from Baseline OAS-M Score. Higher values represent a worse outcome. The OAS-M contains 3 scales: Aggression (Questions \[Q\]1 to 4), Irritability (Q5 to 6), and Suicidality (Q7 to 7b). Aggression total score was calculated by summing the weighted scores in Q1 to 4. Scores for each question ranged from 0 (no events) to 5 (very severe events). Total scores ranged from 0 (no aggression) to any number with no upper limit depending on the frequency of aggressive behavior in a week.

Time frame:
Comparison of baseline score to score at end of treatment period of 8 weeks
Reported as:
Mean · score on a scale
Overt Aggression Scale Modified (OAS-M) Total Aggression Score
score on a scaleSRX246Placebo
Overt Aggression Scale Modified (OAS-M) Total Aggression Score-29.55 ± 37.343-30.43 ± 34.082

Adverse events

Collected over from first dose of study drug to last follow-up visit, up to 8 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SRX2460/49 (0%)0/49 (0%)9/49 (18.4%)
Placebo0/48 (0%)0/48 (0%)7/48 (14.6%)
Most frequent other events
Most frequent other events
EventSRX246Placebo
HeadacheNervous system disorders3/493/48
DiarrheaGastrointestinal disorders3/492/48
Dry MouthGastrointestinal disorders3/492/48

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)SRX246PlaceboTotal
<=18 years000
Between 18 and 65 years494897
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)SRX246PlaceboTotal
Female202040
Male292857
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SRX246PlaceboTotal
Hispanic or Latino347
Not Hispanic or Latino454388
Unknown or Not Reported112
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SRX246PlaceboTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American293160
White161228
More than one race347
Unknown or Not Reported112
Region of Enrollment
Region of Enrollment(Participants)SRX246PlaceboTotal
United States494897
08

Study locations

7 sites
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30331, United States
  • University of Chicago, Department of Psychiatry
    Chicago, Illinois 60637, United States
  • Psychiatric Care and Research Center
    O'Fallon, Missouri 63368, United States
  • SPRI Clinical Trials, LLC
    Brooklyn, New York 11235, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Lindner Center of HOPE
    Mason, Ohio 45040, United States
  • Rhode Island Hospital, Department of Psychiatry
    Providence, Rhode Island 02903, United States
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2014, a primary completion of May 2016 and a completion of May 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2019, 3 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2014
First posted
Feb 5, 2014
Start
May 2014
Primary completionActual
May 2016
CompletionActual
May 2016
Results first posted
Oct 29, 2019
Last update
Jul 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02055638
Lead sponsor
Azevan Pharmaceuticals
Responsible party
Sponsor
First posted
Feb 5, 2014
Start date
May 2014
Primary completion
May 2016
Completion
May 2016
Results posted
Oct 29, 2019
Last update
Jul 21, 2023

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SRX246

Start the discussion